Erythropoietin liposomal dispersion
US6645522B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 18, 1999 |
| Grant date | Nov 11, 2003 |
| Priority date | — |
| Expiry date | Feb 20, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/183
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a liposome based formulation of erythropoietin comprising:(a) an effective amount of an erythropoietin;(b) a lipidic phase comprising:(i) lecithin or hydrogenated lecithin;(ii) optionally, a charged electropositive or electronegative lipid compound; and(iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterols; and(c) a phosphate buffer.The liposome based parenteral dosage form of the invention is prepared by means of an ethanol injection technique. The composition avoids the need for use of human serum albumin and exhibits superior stability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.